Department of Pediatrics, Army Hospital Research and Referral, Delhi, 110010, India.
CMO, CH-CRPF, Nagpur, India.
Cancer Chemother Pharmacol. 2023 Apr;91(4):331-336. doi: 10.1007/s00280-023-04525-8. Epub 2023 Mar 23.
Hydration before starting high-dose methotrexate (HD-MTX) ensures good renal perfusion and alkaline urinary pH. The duration of pre-hydration is not uniform across protocols. We compared 6-h versus 12-h of pre-hydration for HD-MTX therapy in childhood acute lymphoblastic leukaemia (ALL) at our centre where serial MTX level monitoring is not feasible.
This randomised cross-over study consecutively enrolled children < 12 years with ALL receiving HD-MTX. Children with pre-existing renal disease or those exposed to nephrotoxic drugs were excluded. Two groups receiving 6-h versus 12-h pre-hydration on alternate basis in same patient (each exposed to four cycles of 2-5 g/m of HD-MTX) were compared for HD-MTX induced nephrotoxicity (primary outcome) and other HD-MTX toxicities (HMT) as per common terminology criteria for adverse events (CTCAE-4.0). HD-MTX was administered over 24 h as per BFM-protocol-2009. Solitary MTX levels at 36-h (MTX36) were outsourced and leucovorin (LV) was started at 36 h at 15 mg/m/dose for 6-8 doses 6-hourly depending on MTX36. Hydration fluid was dextrose normal saline with sodium-bicarbonate and administered till last LV dose.
Total 136 HD-MTX cycles in 34 patients (age range 5-144 months) were evaluated. Nephrotoxicity [2/68 (2.9%) in 6-h versus 1/68 (1.5%) in 12-h] and HMT incidence was comparable in two pre-hydration groups. Median MTX36 levels were not affected by duration of hydration irrespective of administered dose of HD-MTX. Median serum creatinine at baseline, post-pre-hydration and at 36-h post start of HD-MTX were comparable.
Reduction of pre-hydration duration does not affect HD-MTX induced nephrotoxicity and MTX36 levels in children < 12 years.
在开始大剂量甲氨蝶呤(HD-MTX)治疗前进行水化可确保良好的肾脏灌注和碱性尿液 pH 值。然而,不同方案中预水化的持续时间并不统一。我们比较了在本中心进行的儿童急性淋巴细胞白血病(ALL)HD-MTX 治疗中 6 小时与 12 小时预水化的效果,本中心无法进行 MTX 水平的连续监测。
这是一项随机交叉研究,连续纳入接受 HD-MTX 治疗的 < 12 岁 ALL 儿童。患有先前存在的肾脏疾病或暴露于肾毒性药物的儿童被排除在外。两组患者在同一患者中交替接受 6 小时与 12 小时预水化(每位患者均接受 4 个 2-5 g/m 的 HD-MTX 周期),根据不良事件通用术语标准(CTCAE-4.0)比较 HD-MTX 诱导的肾毒性(主要结局)和其他 HD-MTX 毒性(HMT)。HD-MTX 按照 BFM-protocol-2009 方案在 24 小时内输注。36 小时时的单剂量 MTX 水平(MTX36)由外部机构检测,LV 在 36 小时时开始,剂量为 15 mg/m/剂量,每 6 小时一次,持续 6-8 次,具体取决于 MTX36。水化液为含有碳酸氢钠的葡萄糖生理盐水,直至最后一次 LV 剂量。
在 34 名患者(年龄 5-144 个月)中评估了总共 136 个 HD-MTX 周期。6 小时预水化组和 12 小时预水化组的肾毒性[2/68(2.9%)与 1/68(1.5%)]和 HMT 发生率相当。无论 HD-MTX 的给药剂量如何,水化时间对 MTX36 水平均无影响。基线、预水化后和 HD-MTX 开始后 36 小时的血清肌酐中位数相似。
在 < 12 岁的儿童中,缩短预水化时间不会影响 HD-MTX 诱导的肾毒性和 MTX36 水平。